These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32374509)

  • 1. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
    Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
    J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy.
    Sikic D; Weyerer V; Geppert CI; Bertz S; Lange F; Taubert H; Wach S; Schmitz-Draeger BJ; Wullich B; Hartmann A; Eckstein M
    Urol Oncol; 2022 Feb; 40(2):63.e19-63.e26. PubMed ID: 34420870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
    Singh R; Ansari JA; Maurya N; Mandhani A; Agrawal V; Garg M
    Clin Genitourin Cancer; 2017 Apr; 15(2):e187-e197. PubMed ID: 27601277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer.
    Hensley PJ; Zetter D; Horbinski CM; Strup SE; Kyprianou N
    Hum Pathol; 2016 Nov; 57():68-77. PubMed ID: 27402302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
    Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
    Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.
    Eckstein M; Matek C; Wagner P; Erber R; Büttner-Herold M; Wild PJ; Taubert H; Wach S; Sikic D; Wullich B; Geppert CI; Compérat EM; Lopez-Beltran A; Montironi R; Cheng L; van der Kwast T; Colecchia M; van Rhijn BWG; Amin MB; Netto GJ; Lehmann J; Stöckle M; Junker K; Hartmann A; Bertz S
    Eur Urol Oncol; 2024 Feb; 7(1):128-138. PubMed ID: 37562993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
    Singh R; Singh UP; Agrawal V; Garg M
    Mol Biol Rep; 2022 Aug; 49(8):7541-7556. PubMed ID: 35593896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment.
    Kiselyov A; Bunimovich-Mendrazitsky S; Startsev V
    Int J Cancer; 2016 Jun; 138(11):2562-9. PubMed ID: 26547270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expressions of EMT markers in pan-RAS-pERK1/2-positive tumors improve diagnosis and prognosis assessment of non-muscle invasive bladder cancer and muscle invasive bladder cancer patients.
    Tripathi K; Maurya N; Goel A; Singhai A; Garg M
    Mol Cell Biochem; 2023 Jun; 478(6):1169-1190. PubMed ID: 36239855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Greater Utility of Molecular Subtype Rather than Epithelial-to-mesenchymal Transition (EMT) Markers for Prognosis in High-risk Non-muscle-invasive (HGT1) Bladder Cancer.
    Compérat E
    Eur Urol; 2020 Nov; 78(5):764. PubMed ID: 32631743
    [No Abstract]   [Full Text] [Related]  

  • 19. Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression.
    Lobo J; Monteiro-Reis S; Guimarães-Teixeira C; Lopes P; Carneiro I; Jerónimo C; Henrique R
    J Transl Med; 2020 Aug; 18(1):303. PubMed ID: 32758253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
    Weyerer V; Stoehr R; Bertz S; Lange F; Geppert CI; Wach S; Taubert H; Sikic D; Wullich B; Hartmann A; Eckstein M
    World J Urol; 2021 Nov; 39(11):4011-4019. PubMed ID: 34259899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.